M-MOXIFLOXACIN TABLET
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
21-09-2022
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE)
Tillgänglig från:
MANTRA PHARMA INC
ATC-kod:
J01MA14
INN (International namn):
MOXIFLOXACIN
Dos:
400MG
Läkemedelsform:
TABLET
Sammansättning:
MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE) 400MG
Administreringssätt:
ORAL
Enheter i paketet:
100
Receptbelagda typ:
Prescription
Terapiområde:
QUINOLONES
Produktsammanfattning:
Active ingredient group (AIG) number: 0142242001; AHFS:
Bemyndigande status:
APPROVED
Tillstånd datum:
2018-02-05
Produktens egenskaper
M-Moxifloxacin Product Monograph _Page 1 of 72_
PRODUCT MONOGRAPH
PR
M-MOXIFLOXACIN
Moxifloxacin tablets
400 mg
(as moxifloxacin hydrochloride)
Manufacturer’s Standard
Antibacterial Agent
Mantra Pharma Inc.
9150 Leduc boulevard, suite 201
Brossard, Quebec
Canada J4Y 0E3
Submission Control No.: 266794
Date of Revision:
SEP
21, 2022
M-Moxifloxacin Product Monograph _Page 2 of 72_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................... 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
...........................................................................................................
5
WARNINGS AND PRECAUTIONS
.........................................................................................
5
ADVERSE REACTIONS
.........................................................................................................
15
DRUG INTERACTIONS
.........................................................................................................
19
DOSAGE AND ADMINISTRATION
.....................................................................................
21
OVERDOSAGE
........................................................................................................................
23
ACTION AND CLINICAL PHARMACOLOGY
....................................................................
24
STORAGE AND STABILITY
.................................................................................................
30
SPECIAL HANDLING INSTRUCTIONS
...............................................................................
31
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................... 31
PART II : SCIENTIFIC INFORMATION
.................................................................................
32
PHARMACEUTICAL
Läs hela dokumentet
